Evidence map›Paper›PMID 20179672›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2010

Retracted: Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma.

Hossein A Hamed, Adly Yacoub, Margaret A Park, Patrick J Eulitt, Rupesh Dash, Devanand Sarkar, Igor P Dmitriev, Maciej S Lesniak, Khalid Shah, Steven Grant and 3 more

RetractedOpen access · bronzeAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Stem cells as cellular vehicles for gene therapy against glioblastoma.International journal of clinical and experimental medicine · 2015
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Current status of gene therapy for brain tumors.Translational research : the journal of laboratory and clinical medicine · 2013
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Hossein A HamedDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Adly YacoubDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Margaret A ParkDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Patrick J EulittDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Rupesh DashDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Devanand SarkarDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Igor P DmitrievDivision of Human Gene Therapy, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Maciej S LesniakThe Brain Tumor Center, The University of Chicago, Chicago, Illinois, USA.
Khalid ShahCenter for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Steven GrantDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; Department of Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
David T CurielDivision of Human Gene Therapy, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Paul B FisherDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Paul DentDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA. Electronic address: pdent@vcu.edu.
Virginia Commonwealth University · USUniversity of Alabama at Birmingham · USGordon Center for Medical Imaging · USUniversity of Chicago · US

Funding

Role of EAAT2 and AEG-1 in Astrocyte Dysfunction and NeurodegenerationP01NS031492 · NINDS · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI VOLSKY, DAVID J · 1993 to 2007
$10.9M
Translational Applications of mda-7/IL-24 in CancerP01CA104177 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FISHER, PAUL B · 2005 to 2009
$6.5M
SIGNALING PATHWAYS REGULATING EPITHELIAL CELL SURVIVALR01DK052825 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI DENT, PAUL · 1999 to 2013
$3.3M
MDA-7: Novel Cancer Therapeutic GeneR01CA097318 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FISHER, PAUL B · 2002 to 2012
$2.8M
Regulatory T Cells and Oncolytic Virotherapy of GliomaR01CA122930 · NCI · UNIVERSITY OF CHICAGO · PI LESNIAK, MACIEJ S · 2008 to 2015
$2.5M
Promotion of Nucleoside Analog Induced Apoptosis by HDIsR01CA063753 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 1994 to 2008
$2.2M
AEG-1: Novel Gene Involved in Malignant GliomaR01CA134721 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FISHER, PAUL B · 2009 to 2013
$1.5M
Pancreatic Cancer Management by Novel Gene Therapy & Dietary AgentsR01CA127641 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FISHER, PAUL B · 2009 to 2012
$1.2M
NCI NIH HHS P01 CA104177NCI NIH HHS P01-CA104177NCI NIH HHS R01 CA063753NCI NIH HHS R01 CA097318NCI NIH HHS R01-CA097318NCI NIH HHS R01-CA108325NCI NIH HHS R01 CA122930NCI NIH HHS R01 CA127641NCI NIH HHS R01 CA134721NCI NIH HHS R01-CA134721NCI NIH HHS R01CA63753NCI NIH HHS R01CA77141NIDDK NIH HHS R01 DK052825NIDDK NIH HHS R01-DK52825NINDS NIH HHS P01 NS031492NINDS NIH HHS P01-NS031492
6 · The paper itself

Abstract

We have explored the mechanism by which inhibition of multiple cytoprotective cell-signaling pathways enhance melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) toxicity toward invasive primary human glioblastoma multiforme (GBM) cells, and whether improving adenoviral infectivity/delivery of mda-7/IL-24 enhances therapeutic outcome in animals containing orthotopic xenografted GBM cells. The toxicity of a serotype 5 recombinant adenovirus to express MDA-7/IL-24 (Ad.5-mda-7) was enhanced by combined molecular or small molecule inhibition of mitogen-activated extracellular regulated kinase (MEK)1/2 and phosphatidyl inositol 3-kinase (PI3K) or AKT; inhibition of mammalian target of rapamycin (mTOR) and MEK1/2; and the HSP90 inhibitor 17AAG. Molecular inhibition of mTOR/PI3K/MEK1 signaling in vivo also enhanced Ad.5-mda-7 toxicity. In GBM cells of diverse genetic backgrounds, inhibition of cytoprotective cell-signaling pathways enhanced MDA-7/IL-24-induced autophagy, mitochondrial dysfunction and tumor cell death. Due partly to insufficient adenovirus serotype 5 gene delivery this therapeutic approach has shown limited success in GBM. To address this problem, we employed a recombinant adenovirus that comprises the tail and shaft domains of a serotype 5 virus and the knob domain of a serotype 3 virus expressing MDA-7/IL-24, Ad.5/3-mda-7. Ad.5/3-mda-7 more effectively infected and killed GBM cells in vitro and in vivo than Ad.5-mda-7. Future combinations of these approaches hold promise for developing an effective therapy for GBM.

Indexed as

Genetic VectorsSignal TransductionAdenoviridaeBrain NeoplasmsGlioblastomaHumansInterleukin-24InterleukinsTreatment OutcomeInterleukin-24Interleukins

Identifiers

PMID20179672
PMCPMC2889737
OpenAlexW2081941885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.